3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Imatinib Mesylate
8
venetoclax
6
Cytarabine
5
ponatinib
4
nilotinib
4
Azacitidine
4
zosuquidar trihydrochloride
2
fludarabine
2
bosutinib
2
RO6839921
2
Decitabine
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
spartalizumab
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
pegfilgrastim
1
lestaurtinib
1
gilteritinib
1
flumatinib
1
enasidenib
1
emvododstat
1
blinatumomab
1
asciminib
1
Whole-Body Irradiation
1
N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
1
Lenalidomide
1
Immunotherapy, Adoptive
1
Idarubicin
1
IMC-EB10
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts